Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-02-08

Clinical Trial Update: Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions [Phase 3]

View source ↗

Summary

Phase 3 study of a 2.25 mm sirolimus-eluting stent for coronary artery lesions has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cypher Sirolimus-Eluting Stent (2.25 mm) (sirolimus-eluting stent)

Snippet

Sponsor: Cordis US Corp. | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-02-08